CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy

  • Khan, Tashbib
  • Lyons, Nicholas J.
  • Gough, Madeline
  • Kwah, Kayden K.X.
  • Cuda, Tahleesa J.
  • Snell, Cameron E.
  • Tse, Brian W.
  • Sokolowski, Kamil A.
  • Pearce, Lesley A.
  • Adams, Timothy E.
  • Rose, Stephen E.
  • Puttick, Simon
  • Pajic, Marina
  • Adams, Mark N.
  • He, Yaowu
  • Hooper, John D.
  • Kryza, Thomas
Publication date
January 2022
Publisher
Ivyspring International Publisher

Abstract

Rationale: An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein enriched on malignant cells. Multiple ADCs are currently used clinically as anti-cancer agents significantly improving patient survival. Herein, we evaluated the rationale of targeting the cell surface oncoreceptor CUB domain-containing protein 1 (CDCP1) using ADCs and assessed the efficacy of CDCP1-directed ADCs against a range of malignant tumors. Methods: CDCP1 mRNA expression was evaluated using large transcriptomic datasets of normal/tumor samples for 23 types of cancer and 15 other normal organs, and CDCP1 protein expression was examined in 34 normal tissues, >300 samples from six ty...

Extracted data

We use cookies to provide a better user experience.